Compound to Control Presbyopia Symptoms

NCT05006898 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2021-08-19

No results posted yet for this study

Summary

Low dose compose to control presbyopia symptoms

Conditions

Interventions

COMBINATION_PRODUCT

PBO to control presbyopia symptoms

Low dose PBO to control presbyopia symptoms

Sponsors & Collaborators

  • Optall Vision

    lead OTHER

Principal Investigators

  • Cesar Alejandro S Galeana · Optall Vision

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2020-07-01
Completion
2020-07-01

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05006898 on ClinicalTrials.gov